OBJECTIVES:  This study aims to analyze the evolution of the consumption pattern of the antipsychotic drugs (APs) in Russian Federation. METHODS:  The sales data of the antipsychotic drugs in Russian Federation during the period 2010-2015 was retrieved from the DSM-group marketing database and subsequently analyzed. The drugs have been classified into typical antipsychotics (TA), atypical antipsychotics (AA) and sustained-action APs. Consumption data have been expressed in daily-defined dose (DDD) per 1,000 inhabitants per day of treatment (DDD/1000/day) total for hospital, retail and reimbursable pharmaceuticals. The total number of DDD/1000/day was calculated for Russian Federation on the whole, as well as for each federal district, region and republic of the Russian Federation, by adding up the DDD/1000/day for the individual antidepressants. RESULTS:  Antipsychotic consumption decreased from 3.80 in 2010 to 3.59 DDD/1000/day in 2015 (∆ -5.5%). TA consumption decreased (from 61% in 2010 to 55% in 2015) and that of the AA and sustained-action APs ones increased (from 17% (2010) to 19% (2015) and from 22% (2010) to 26% (2015) respectively). In 2010, the most consumed drug was haloperidol oral (0.99 DDD/1000/day). However, during the period 2010-2015 utilization of haloperidol oral decreased by 23%, but it remains the most consumed APs (0.76 DDD/1000/day) in 2015. The drug with the largest increase in consumption was olanzapine oral. Its consumption increased in three times in the period 2010 - 2015 (from 0.027 to 0.080 DDD/1000/day). CONCLUSIONS:  It was found that the APs consumption in Russian Federation during the period 2010-2015 has not changed significantly (∆ -5.5%). At the same time TA (1-st generation drugs) consumption decreased and that of the AA and sustained-action APs ones increased. Therefore, the level of consumption of TA in Russian Federation remains high (over 50% of the total APs consumption).